Select Language
FGF R3 (IIIc)
FGF R3 (IIIc) Overview
| English Name | Fibroblast growth factor receptor 3 | Approved Drugs | 9 |
| Drugs in Clinical Trials | 30 | Target Synonym | Fibroblast Growth Factor Receptor 3-S，EC:2.7.10.1，EC 2.7.10，JTK4，CD333，FGFR3，Fibroblast Growth Factor Receptor 3，FGFR-3，Fibroblast Growth Factor Receptor 3 Variant 4，Achondroplasia， Thanatophoric Dwarfism，Hydroxyaryl-Protein Kinase，Tyrosine Kinase JTK4，CD333 Antigen，EC 2.7.10.1，HSFGFR3EX，CEK2，ACH，Receptor， Fibroblast Growth Factor， Type 3 |
| Highest Development Stage | Approved | ||
| English Name | Fibroblast growth factor receptor 3 |
| Target Synonym | Fibroblast Growth Factor Receptor 3-S，EC:2.7.10.1，EC 2.7.10，JTK4，CD333，FGFR3，Fibroblast Growth Factor Receptor 3，FGFR-3，Fibroblast Growth Factor Receptor 3 Variant 4，Achondroplasia， Thanatophoric Dwarfism，Hydroxyaryl-Protein Kinase，Tyrosine Kinase JTK4，CD333 Antigen，EC 2.7.10.1，HSFGFR3EX，CEK2，ACH，Receptor， Fibroblast Growth Factor， Type 3 |
| Approved Drugs | 9 |
| Drugs in Clinical Trials | 30 |
| Highest Development Stage | Approved |
FGF R3 (IIIc) Product List
- Product Category
Protein (1)
- Product Status
Launched (1)
- Species
Human (1)
- Tag
Fc Tag (1)
- Conjugate
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
FGC-H5256 |  Human | HEK293 | Human FGF R3 (IIIc) / FGF R3C / CD333 Protein, Fc Tag, low endotoxin (MALS verified) |  |  |  |
Total: 1
- 1
FGF R3 (IIIc) Background
Fibroblast growth factor receptors (FGFR) are transmembrane kinase proteins with growing importance in cancer biology given the frequency of molecular alterations and vast interface with multiple other signaling pathways. The FGFR3 gene is at the human chromosomal locus 4p16.3 also encodes two isoforms: FGF R3 (IIIb) FGF R3 (IIIc). Upregulated expression of FGFR3 protein is also found in a significant number of tumors. Additionally, FGFR3 has been found to trigger resistance to tamoxifen via the activation of the PLCγ signaling cascade.
FGF R3 (IIIc) Synonyms
FGF R3 (IIIc),FGF R3C,CD333
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Infigratinib | BGJ-398 phosphate; BGJ-398; NVP-BGJ398; BBP-831; KK8398 | Phase 3 Clinical | Novartis Pharma Ag | Achondroplasia; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Glioma; Hematologic Neoplasms; Nasopharyngeal Neoplasms; Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Rectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| Vepugratinib | LOXO-435; LY3866288; LY-3866288; LOX-24350 | Phase 3 Clinical | Eli Lilly And Company | Carcinoma, Transitional Cell; Neoplasm Metastasis; Neoplasms; Solid tumours; Ureteral Neoplasms; Urinary Bladder Neoplasms | Details |
| SC-0011 | SC-0011 | Phase 3 Clinical | Shijiazhuang Zhikang Hongren New Drug Development Co Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Zoligratinib | CH-5183284; FF-284; Debio-1347 | Phase 2 Clinical | Chugai Pharmaceutical Co Ltd | Breast Neoplasms; Solid tumours | Details |
| AUR-109 | ODM-203; AUR-109 | Phase 2 Clinical | Orion Corp | Breast Neoplasms; Carcinoma, Renal Cell; Colorectal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pulmonary Fibrosis; Solid tumours; Urinary Bladder Neoplasms | Details |
| Lucitanib | S-80881; AL-3810; CO-3810; E-3810; S-80881-2 | Phase 2 Clinical | Advenchen Laboratories Nanjing Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Metastatic breast cancer; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thymus Neoplasms | Details |
| Rogaratinib | BAY-1163877 | Phase 2 Clinical | Bayer AG | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Gastrointestinal Stromal Tumors; Metastatic breast cancer; Neoplasms; Sarcoma; Solid tumours; Urinary Bladder Neoplasms | Details |
| Fexagratinib | AZD4547; AZD-4547; ABSK-091; ABSK091 | Phase 2 Clinical | Astrazeneca Plc | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Foodborne Diseases; Gastrointestinal Diseases; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Derazantinib | ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 | Phase 2 Clinical | Arqule Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Transitional Cell; Cholangiocarcinoma; Solid tumours; Stomach Neoplasms; Urogenital Neoplasms | Details |
| Dabogratinib | TYRA-300; TYRA300 | Phase 2 Clinical | Tyra Biosciences Inc | Achondroplasia; Carcinoma; Carcinoma, Transitional Cell; Solid tumours; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
| Inhaled Nintedanib – dry powder (Avalyn Pharma) | AP02; AP 02 DP; AP-02; AP02-DP | Phase 2 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Respiratory Tract Diseases | Details |
| ABSK-061 | ABSK061 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Achondroplasia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Solid tumours | Details |
| PZH-2111 | PZH2111; PZH-2111 | Phase 2 Clinical | Zhangzhou Pientzehuang Pharmaceutical Co Ltd | Cholangiocarcinoma; Solid tumours | Details |
| Gunagratinib | ICP-192 | Phase 2 Clinical | Beijing Tiancheng Pharmaceutical Technology Co Ltd | Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Head and Neck Neoplasms; Lung Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| Recifercept | PF-07256472; TA-46 | Phase 1 Clinical | Pfizer Inc | Achondroplasia | Details |
| BPI-17509 | BPI-17509 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | Details |
| HH185 | 3D-185; 3-D185; HH-185; 3D185 | Phase 1 Clinical | ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, Shanghai Medicilon Inc | Solid tumours | Details |
| nintedanib (Avalyn Pharma) | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| TYRA-200 | TYRA200; TYRA-200 | Phase 1 Clinical | Tyra Biosciences Inc | Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Solid tumours | Details |
| ASN-8639 | ASN-8639; ASN8639 | Phase 1 Clinical | Asieris Pharmaceuticals Ltd | Solid tumours | Details |
| Nintedanib Esylate Inhalation Powder(Cspc) | Phase 1 Clinical | Cspc-Nbp Pharmaceutical Co Ltd | Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis | Details | |
| Fibroblast growth factor receptor 3 (Eli Lilly and Company) | Phase 1 Clinical | Eli Lilly And Company | Neoplasms | Details | |
| GR-1017 | GR-1017; GQ-1011; AMB-302; BHV-1530 | Phase 1 Clinical | Aimed Bio Inc, GeneQuantum Healthcare (Suzhou) Co Ltd | Carcinoma, Transitional Cell; Solid tumours | Details |
| TYRA-430 | TYRA-430 | Phase 1 Clinical | Tyra Biosciences Inc | Carcinoma, Hepatocellular; Neoplasms; Solid tumours | Details |
| MNKD-201 | MNKD-201; MKND-201 | Phase 1 Clinical | MannKind Corp | Idiopathic Pulmonary Fibrosis | Details |
| TYRA-300-B01 | TYRA-300-B01 | Phase 1 Clinical | Tyra Biosciences Inc | Details | |
| SAR-442501 | SAR-442501 | Phase 1 Clinical | Sanofi | Achondroplasia; Osteochondrodysplasias | Details |
| TT-00434 | TT-00434 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours; Urinary Bladder Neoplasms | Details |
| ABSK-121 | ABSK121-NX; ABSK121 | Phase 1 Clinical | ABbisko Therapeutics Co Ltd | Solid tumours | Details |
| CPL-304110 | CPL-304110; CPL-304-110 | Phase 1 Clinical | Celon Pharma Sa | Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Sarcoma; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Anlotinib Dihydrochloride | AL-3818 | Approved | Advenchen Laboratories Llc, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 福可维 | Mainland China | Carcinoma, Non-Small-Cell Lung | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 2018-05-08 | Bile Duct Diseases; Bone Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Colorectal Neoplasms; Craniopharyngioma; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Fallopian Tube Neoplasms; Gallbladder Neoplasms; Gastroenteropancreatic neuroendocrine tumor; Gastroesophageal Junction Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Head and Neck Neoplasms; Hepatic Insufficiency; Leiomyosarcoma; Liver Dysfunction; Lung Diseases, Interstitial; Lung Neoplasms; Lymphoma, Large B-Cell, Diffuse; Medullary thyroid cancer (MTC); Melanoma; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms; Neuroendocrine Tumors; Osteoma; Ovarian Neoplasms; Peritoneal Neoplasms; Sarcoma; Sarcoma, Alveolar Soft Part; Sarcoma, Synovial; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Thoracic Neoplasms; Thyroid Neoplasms; Urologic Neoplasms; Uterine Cervical Neoplasms | Details |
| Lenvatinib Mesilate | E-7080; MK-7902; ER-203492-00 | Approved | Eisai Co Ltd | Kisplyx, Lenvima, Lenvima/Kisplyx, 乐卫玛 | United States | Thyroid Neoplasms | Eisai Inc | 2015-02-13 | Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Follicular; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Adenoid Cystic; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Glioma; Hepatic Insufficiency; Liver Diseases; Liver Neoplasms; Lymphoma; Melanoma; Neoplasm Metastasis; Neoplasms; Neuroendocrine Tumors; Osteosarcoma; Ovarian Neoplasms; Paraganglioma; Pheochromocytoma; Renal Insufficiency; Solid tumours; Stomach Neoplasms; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Uterine Cervical Neoplasms | Details |
| Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim International Gmbh | 2014-10-15 | Adenocarcinoma, Clear Cell; Appendiceal Neoplasms; Asbestosis; Astrocytoma; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Endometrial Stromal Tumors; Esophageal Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Gliosarcoma; Hepatic Insufficiency; Idiopathic Pulmonary Fibrosis; Leukemia, Myeloid, Acute; Lung Diseases, Interstitial; Mesothelioma; Multiple Myeloma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Pulmonary Fibrosis; Radiation Pneumonitis; Rejection of lung transplantation; Sarcoma; Scleroderma, Systemic; Silicosis; Small Cell Lung Carcinoma; Solid tumours; systemic sclerosis-associated interstitial lung disease; Telangiectasia, Hereditary Hemorrhagic; Uterine Neoplasms | Details |
| Futibatinib | TAS-120 | Approved | Otsuka Pharmaceutical Co Ltd, Taiho Pharmaceutical Co Ltd | LYTGOBI | United States | Cholangiocarcinoma | Taiho Oncology Inc | 2022-09-30 | Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Lymphoma; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Sarcoma; Solid tumours; Stomach Neoplasms | Details |
| Selpercatinib | LOXO-292; LY-3527723; ARRY-192; Ret-IN-1 | Approved | Array Biopharma | Retevmo, Retsevmo, 睿妥 | United States | Medullary thyroid cancer (MTC); Thyroid Neoplasms; Carcinoma, Non-Small-Cell Lung | Eli Lilly And Company | 2020-05-08 | Anorexia; Cachexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Ependymoma; Fibrosarcoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medullary thyroid cancer (MTC); Medulloblastoma; Myofibromatosis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Poorly Differentiated Thyroid Gland Carcinoma; Renal Insufficiency; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Wilms Tumor | Details |
| Pemigatinib | INCB-054828; INCB-54828; IBI-375 | Approved | Incyte Corp | Pemazyre, 伯坦, 达伯坦 | United States | Cholangiocarcinoma | Incyte Corp | 2020-04-17 | Adenocarcinoma; Bile Duct Neoplasms; Biliary Tract Neoplasms; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colitis, Ulcerative; Colorectal Neoplasms; Endometrial Neoplasms; Gastrointestinal Stromal Tumors; Glioblastoma; Lung Neoplasms; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myeloproliferative Disorders; Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Translocation, Genetic; Urinary Bladder Neoplasms; Urologic Neoplasms | Details |
| Pazopanib Hydrochloride | GSK-786034; GW-786034B; SB-786034; GW-786034 | Approved | Glaxosmithkline Plc, Novartis Pharma Ag | 维全特, Armala, Votrient, Patorma | United States | Carcinoma, Renal Cell; Sarcoma | Novartis Pharma Ag | 2009-10-19 | Adenocarcinoma, Follicular; Brain Neoplasms; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma, Embryonal; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Chondrosarcoma; Chondrosarcoma, Extraskeletal Myxoid; Choriocarcinoma; Colorectal Neoplasms; Dermatofibrosarcoma; Endodermal Sinus Tumor; Epistaxis; Fallopian Tube Neoplasms; Fibromatosis, Aggressive; Gastrinoma; Gastroenteropancreatic neuroendocrine tumor; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genital Neoplasms, Female; Germinoma; Glioblastoma; Glioma; Gliosarcoma; Glucagonoma; Hemangiosarcoma; Herpes Genitalis; Herpes Simplex; HIV Infections; Hormone-Resistant Prostate Neoplasms; Insulinoma; Leiomyosarcoma; Leukemia, Myeloid, Acute; Liposarcoma; Lung Neoplasms; Lymphoma; Macular Degeneration; Medullary thyroid cancer (MTC); Melanoma; Mesothelioma; Multiple Endocrine Neoplasia T | Details |
| Tasurgratinib | E-7090 | Approved | Eisai Co Ltd | TASFYGO | Japan | Biliary Tract Neoplasms | Eisai Co Ltd | 2024-09-24 | Biliary Tract Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Hepatic Insufficiency; Neoplasms; Solid tumours | Details |
| Erdafitinib | 890E37NHMV; G-024; JNJ-493; JNJ-42756493; TAR-210 | Approved | Astex Pharmaceuticals Inc | Balversa, 博珂 | United States | Carcinoma, Transitional Cell | Janssen Biotech Inc | 2019-04-12 | Adenocarcinoma; Bile Duct Neoplasms; Bone metastases; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Central Nervous System Neoplasms; Ependymoma; Esophageal Neoplasms; Glioma; Hepatic Insufficiency; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Metastatic breast cancer; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
Contact Us
BettinastraBe 30, 60325 Frankfurt am Main